bioAffinity Technologies, Inc.
BIAFbioAffinity Technologies is a biotechnology company focused on the development of noninvasive diagnostic laboratory tests and targeted cancer therapeutics.
Earnings
Next report
Nov 18, 2026 (in 2 months)Competitors
By market cap
Profile
bioAffinity Technologies is a biotechnology company focused on the development of noninvasive diagnostic laboratory tests and targeted cancer therapeutics. The company utilizes a proprietary platform combining flow cytometry with automated AI-driven analysis to detect early-stage lung cancer and other respiratory diseases. Its core value proposition lies in providing high-sensitivity, cost-effective diagnostic tools that reduce the need for invasive procedures and improve patient outcomes through early detection.
A developer of a first-of-its-kind balanced diagnostic test that combines flow cytometry and AI to achieve high sensitivity and specificity for early-stage lung cancer detection.
FAQ
- What is bioAffinity Technologies, Inc.'s market cap?
- bioAffinity Technologies, Inc. (BIAF) has a market capitalization of $3.2M and trades on NASDAQ.
- Who are bioAffinity Technologies, Inc.'s competitors?
- bioAffinity Technologies, Inc.'s key competitors include Biodesix, Veracyte, Guardant Health, and others. These companies compete in similar markets and product categories.
- Who does bioAffinity Technologies, Inc. partner with?
- bioAffinity Technologies, Inc.'s notable partners include Cardinal Health, ICU Medical, University of Texas at San Antonio, and others.
- What subsidiaries does bioAffinity Technologies, Inc. have?
- bioAffinity Technologies, Inc.'s subsidiaries include Precision Pathology Laboratory Services (PPLS), OncoSelect Therapeutics, LLC.
- Where is bioAffinity Technologies, Inc. headquartered?
- bioAffinity Technologies, Inc. is headquartered in United States of America and employs approximately 75 people. It has been publicly traded since 2022.